Outlook Therapeutics, Inc. (OTLK) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-03

Outlook Therapeutics, Inc. (OTLK) has filed 6 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-03. 10 Form 8-K material event filings were reported by OTLK in the last 90 days. InsiderAlpha tracks every OTLK SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Outlook Therapeutics, Inc. (OTLK)

SIC classification	Biological Products, (No Diagnostic Substances) (SIC 2836)
SEC CIK	0001649989

90-Day SEC Filing Activity

Form 4 filings (90d)	6
Form 8-K filings (90d)	10
Latest Form 4 filing	2026-06-03

Recent OTLK Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-02	Haddadin Yezan Munther	Director	P — Open-market purchase	29.0K	$0.83	$24K	SEC
2026-05-28	Sukhtian Ghiath M.	Insider	P — Open-market purchase	8.54M	$0.59	$5.00M	SEC
2026-05-27	Sukhtian Faisal Ghiath	Director	P — Open-market purchase	122.2K	$0.41	$50K	SEC
2026-05-26	Haddadin Yezan Munther	Director	P — Open-market purchase	34.0K	$0.44	$15K	SEC
2026-05-26	THURMAN RANDY H	Director	P — Open-market purchase	5.0K	$0.43	$2K	SEC
2026-05-26	HILZINGER KURT J	Director	P — Open-market purchase	400.0K	$0.44	$177K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Outlook Therapeutics, Inc. (OTLK). Updated in real time as new filings are submitted to the SEC.

Most-Active OTLK Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Sukhtian Ghiath M.	7	$5.00M
Haddadin Yezan Munther	2	$39K
HILZINGER KURT J	1	$177K
THURMAN RANDY H	1	$2K
Sukhtian Faisal Ghiath	1	$50K

Recent OTLK Form 8-K Material Events

2026-06-26 — Item 3.01 [SEC]
2026-06-16 — Item 8.01, 9.01 [SEC]
2026-06-01 — Item 8.01, 9.01 [SEC]
2026-05-29 — Item 8.01, 9.01 [SEC]
2026-05-28 — Item 8.01, 9.01 [SEC]

Recent Insider Filings

2026-06-03 — Haddadin Yezan Munther (Director)
2026-06-02 — Sukhtian Ghiath M. (Insider)
2026-05-27 — Sukhtian Faisal Ghiath (Director)
2026-05-27 — Haddadin Yezan Munther (Director)
2026-05-27 — THURMAN RANDY H (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in OTLK insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

OTLK Insider Trading — FAQ

What is the latest insider trade for OTLK?: Outlook Therapeutics, Inc. (OTLK) had 6 insider filings in the last 90 days, with the most recent on 2026-06-03. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying OTLK stock?: 0 insider purchases of OTLK were filed in the last 90 days.
How many insiders are selling OTLK stock?: 0 insider sales of OTLK were filed in the last 90 days.
Where can I see OTLK SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every OTLK SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live OTLK dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.